Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (241-250 of 785) with videos related to

Pageof 79
Sort By:
Journal of Diabetes Investigation|November 10, 2018
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME<sup>®</sup> trialTakashi Kadowaki, Masaomi Nangaku, Stefan Hantel, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 22, 2012
Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonanceTheresa Reiter, Oliver Ritter, Martin R Prince, et al.
Journal of the American College of Cardiology|March 20, 2019
Influence of Microvascular Disease on Cardiovascular Events in Type 2 DiabetesSubodh Verma, Christoph Wanner, Isabella Zwiener, et al.
The New England Journal of Medicine|July 22, 2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisChristoph Wanner, Vera Krane, Winfried März, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 10, 2018
Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance HemodialysisTill Keller, Christoph Wanner, Vera Krane, et al.
BMJ Open|September 13, 2018
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 studyHolger Reinecke, Sabine Jürgensmeyer, Christiane Engelbertz, et al.
Open Heart|January 12, 2025
Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)Kolja Lau, Victoria Sokalski, Lora Lorenz, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 8, 2011
Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney diseaseMartin Wagner, Ahsan Alam, Josef Zimmermann, et al.
The Journal of Clinical Endocrinology and Metabolism|March 15, 2022
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?Priyadarshini Balasubramanian, Christoph Wanner, João Pedro Ferreira, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2013
What guidelines should or should not be: implications for guideline productionWim Van Biesen, Sabine N van der Veer, Kitty J Jager, et al.
Pageof 79

Showing results (241-250 of 785) with videos related to

Sort By:
Pageof 79
Journal of Diabetes Investigation|November 10, 2018
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME<sup>®</sup> trialTakashi Kadowaki, Masaomi Nangaku, Stefan Hantel, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 22, 2012
Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonanceTheresa Reiter, Oliver Ritter, Martin R Prince, et al.
Journal of the American College of Cardiology|March 20, 2019
Influence of Microvascular Disease on Cardiovascular Events in Type 2 DiabetesSubodh Verma, Christoph Wanner, Isabella Zwiener, et al.
The New England Journal of Medicine|July 22, 2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisChristoph Wanner, Vera Krane, Winfried März, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 10, 2018
Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance HemodialysisTill Keller, Christoph Wanner, Vera Krane, et al.
BMJ Open|September 13, 2018
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 studyHolger Reinecke, Sabine Jürgensmeyer, Christiane Engelbertz, et al.
Open Heart|January 12, 2025
Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)Kolja Lau, Victoria Sokalski, Lora Lorenz, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 8, 2011
Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney diseaseMartin Wagner, Ahsan Alam, Josef Zimmermann, et al.
The Journal of Clinical Endocrinology and Metabolism|March 15, 2022
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?Priyadarshini Balasubramanian, Christoph Wanner, João Pedro Ferreira, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2013
What guidelines should or should not be: implications for guideline productionWim Van Biesen, Sabine N van der Veer, Kitty J Jager, et al.
Pageof 79